Triple-negative breast cancers and the human mammary epithelial cell hierarchy

Breast Disease

Volumn 32, Issue 1-2, 2010, Pages 49-61

  Ganesan, Shridar ^a   Karantza, Vassiliki ^a   Oza, Jay ^a   Toppmeyer, Deborah ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA6 INTEGRIN; BETA1 INTEGRIN; BRCA1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CYTOKERATIN 15; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; GLYCOPROTEIN P; HERMES ANTIGEN; MUCIN 1; PROGESTERONE RECEPTOR; PROTEIN BCL 2; STAGE SPECIFIC EMBRYO ANTIGEN 4; UVOMORULIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST STEM CELL; CANCER STEM CELL; CELL DIFFERENTIATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; METAPLASTIC BREAST CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; SIDE POPULATION CELL; STEM CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 80755169604     PISSN: 08886008     EISSN: 15581551     Source Type: Journal    
DOI: 10.3233/BD-2010-0322     Document Type: Article

References (114)

1. I. Ben-Porath et al., An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors, Nat Genet 40 (2008), 499-507. (Pubitemid 351601215)
2. H. Nakshatri, E.F. Srour and S. Badve, Breast cancer stem cells and intrinsic subtypes: controversies rage on, Curr Stem Cell Res Ther 4 (2009), 50-60.
3. S.Y. Park et al., Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer, Clin Cancer Res 16 (2010), 876-887.
4. P.S. Rudland, Epithelial stem cells and their possible role in the development of the normal and diseased human breast, Histol Histopathol 8 (1993), 385-404. (Pubitemid 23125715)
5. S. Liu et al., BRCA1 regulates human mammary stem/progenitor cell fate, Proc Natl Acad Sci U S A 105 (2008), 1680-1685. (Pubitemid 351346574)
6. G. Farnie and R.B. Clarke, Mammary stem cells and breast cancer-role of Notch signalling, Stem Cell Rev 3 (2007), 169-175. (Pubitemid 350129719)
7. E. Lerma, A. Barnadas and J. Prat, Triple negative breast carcinomas: similarities and differences with basal like carcinomas, Appl Immunohistochem Mol Morphol 17 (2009), 483-494.
8. P. Carotenuto et al., Triple negative breast cancer: from molecular portrait to therapeutic intervention, Crit Rev Eukaryot Gene Expr 20 (2010), 17-34.
9. A.A. Thike et al., Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer, Mod Pathol 23 (2010), 123-133.
10. C.M. Perou et al., Distinctive gene expression patterns in human mammary epithelial cells and breast cancers, Proc Natl Acad Sci U S A 96 (1999), 9212-9217. (Pubitemid 29374734)
11. C.M. Perou et al., Molecular portraits of human breast tumours, Nature 406 (2000), 747-752.
12. T. Sorlie et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A 98 (2001), 10869-10874. (Pubitemid 32878711)
13. T. Sorlie et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A 100 (2003), 8418-8423. (Pubitemid 36842560)
14. L.H. Saal et al., Recurrent grossmutations of the PTENtumor suppressor gene in breast cancers with deficient DSB repair, Nat Genet 40 (2008), 102-107.
15. B. Marty et al., Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells, Breast Cancer Res 10 (2008), R101.
16. E. Manie et al., High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors, Cancer Res 69 (2009), 663-671.
17. A. Langerod et al., TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer, Breast Cancer Res 9 (2007), R30.
18. M.C. Cheang et al., Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res 14 (2008), 1368-1376. (Pubitemid 351413917)
19. N.Kuroda et al., Themajority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma, Med Mol Morphol 42 (2009), 128-131.
20. T.O. Nielsen et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res 10 (2004), 5367-5374. (Pubitemid 39100473)
21. S. Pintens et al., Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1, J Clin Pathol 62 (2009), 624-628.
22. F. Bertucci et al., How basal are triple-negative breast cancers? Int J Cancer 123 (2008), 236-240. (Pubitemid 351705215)
23. + breast cancers correlates with lower recurrence rates, Cancer Res 67 (2007), 10669-10676. (Pubitemid 350145892)
24. R.M. Neve et al., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell 10 (2006), 515-527. (Pubitemid 44854747)
25. J. Kao et al., Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery, PLoS One 4 (2009), e6146.
26. E. Charafe-Jauffret et al., Gene expression profiling of breast cell lines identifies potential new basal markers, Oncogene 25 (2006), 2273-2284.
27. E.A. Rakha et al., Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes, Clin Cancer Res 15 (2009), 2302-2310.
28. A. Prat et al., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res 12 (2010), R68.
29. J.I. Herschkowitz et al., Identification of conserved gene expression features between murinemammary carcinoma models and human breast tumors, Genome Biol 8 (2007), R76.
30. J.H. Taube et al., Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes, Proc Natl Acad Sci U S A 107 (2010), 15449-15454.
31. B. Weigelt B. Kreike and J.S. Reis-Filho, Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis, Breast Cancer Res Treat 117 (2009), 273-280.
32. J.A. Gilbert et al., Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy, Mol Cancer Ther 7 (2008), 944-951. (Pubitemid 351551048)
33. S. Vranic et al., Adenoid cystic carcinomas of the breast have low Topo IIalpha expression but frequently overexpress EGFR protein without EGFR gene amplification, Hum Pathol, (2010).
34. C. Marchio, B. Weigelt and J.S. Reis-Filho, Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas), J Clin Pathol 63 (2010), 220-228.
35. J.E. Visvader, Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis, Genes Dev 23 (2009), 2563-2577.
36. R. Villadsen et al., Evidence for a stem cell hierarchy in the adult human breast, J Cell Biol 177 (2007), 87-101. (Pubitemid 46588404)
37. O.W. Petersen and K. Polyak, Stem cells in the human breast, Cold Spring Harb Perspect Biol 2 (2010), a003160.
38. Y.C. Tsai et al., Contiguous patches of normal human mammary epithelium derived from a single stemcell: implications for breast carcinogenesis, Cancer Res 56 (1996), 402-404. (Pubitemid 26026371)
39. M. Shackleton et al., Generation of a functional mammary gland from a single stem cell, Nature 439 (2006), 84-88. (Pubitemid 43053633)
40. F. Vaillant et al., The emerging picture of the mouse mammary stem cell, Stem Cell Rev 3 (2007), 114-123. (Pubitemid 350129714)
41. J. Regan and M. Smalley, Prospective isolation and functional analysis of stem and differentiated cells from the mouse mammary gland, Stem Cell Rev 3 (2007), 124-136. (Pubitemid 350129715)
42. M.L.Asselin-Labat et al., Delineating the epithelial hierarchy in themousemammary gland, Cold SpringHarb SympQuant Biol 73 (2008), 469-478.
43. J. Stingl et al., Purification and unique properties of mammary epithelial stem cells, Nature 439 (2006), 993-997. (Pubitemid 43292419)
44. E. Charafe-Jauffret, C. Ginestier and D. Birnbaum, Breast cancer stem cells: tools and models to rely on, BMC Cancer 9 (2009), 202.
45. M. Bentires-Alj et al., It's all in the details: methods in breast development and cancer, Breast Cancer Res 11 (2009), 305.
46. J. Stingl, Detection and analysis of mammary gland stem cells, J Pathol 217 (2009), 229-241.
47. J. Stingl, J.T. Emerman and C.J. Eaves, Enzymatic dissociation and culture of normal human mammary tissue to detect progenitor activity, Methods Mol Biol 290 (2005), 249-263.
48. B.A. Reynolds and S.Weiss, Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell, Dev Biol 175 (1996), 1-13. (Pubitemid 26150042)
49. G. Dontu et al., In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells, Genes Dev 17 (2003), 1253-1270. (Pubitemid 36583168)
50. M.J. Liao et al., Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity, Cancer Res 67 (2007), 8131-8138.
51. L.G. Sheffield and C.W. Welsch, Transplantation of human breast epithelia to mammary-gland-free fat-pads of athymic nude mice: influence of mammotrophic hormones on growth of breast epithelia, Int J Cancer 41 (1988), 713-719.
52. L.G. Sheffield, Organization and growth of mammary epithelia in the mammary gland fat pad, J Dairy Sci 71 (1988), 2855-2874.
53. K. Hoshino and W.U. Gardner, Transplantability and life span ofmammary gland during serial transplantation inmice, Nature 213 (1967), 193-194.
54. C. Kuperwasser et al., Reconstruction of functionally normal and malignant human breast tissues in mice, Proc Natl Acad Sci U S A 101 (2004), 4966-4971. (Pubitemid 38469186)
55. D.A. Proia and C. Kuperwasser, Reconstruction of human mammary tissues in a mouse model, Nat Protoc 1 (2006), 206-214.
56. M. Wu et al., Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice, Proc Natl Acad Sci U S A 106 (2009), 7022-7027.
57. P. Eirewet al., Amethod for quantifying normal humanmammary epithelial stem cells with in vivo regenerative ability, Nat Med 14 (2008), 1384-1389.
58. J. Stingl et al., Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast, Differentiation 63 (1998), 201-213. (Pubitemid 28428734)
59. J. Stingl et al., Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue, Breast Cancer Res Treat 67 (2001), 93-109. (Pubitemid 32744490)
60. E. Lim et al., Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers, Nat Med 15 (2009), 907-913.
61. A. Raouf et al., Transcriptome analysis of the normal human mammary cell commitment and differentiation process, Cell Stem Cell 3 (2008), 109-118.
62. J.S. Moreb, Aldehyde dehydrogenase as a marker for stem cells, Curr Stem Cell Res Ther 3 (2008), 237-246.
63. C. Ginestier et al., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, Cell Stem Cell 1 (2007), 555-567. (Pubitemid 350056407)
64. S. Corti et al., Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity, Stem Cells 24 (2006), 975-985. (Pubitemid 44464730)
65. M.R. Heerma van Voss et al., Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers, Breast Cancer Res Treat 123 (2010), 611-612.
66. G.A. Challen and M.H. Little, A side order of stem cells: the SP phenotype, Stem Cells 24 (2006), 3-12.
67. M.A. Goodell et al., Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species, Nat Med 3 (1997), 1337-1345. (Pubitemid 28011033)
68. M.J. Smalley and R.B. Clarke, The mammary gland "side population": a putative stem/progenitor cell marker? JMammary Gland Biol Neoplasia 10 (2005), 37-47. (Pubitemid 40724021)
69. H. Clayton, I. Titley and M. Vivanco, Growth and differentiation of progenitor/stem cells derived from the human mammary gland, Exp Cell Res 297 (2004), 444-460. (Pubitemid 38798406)
70. A.J. Alvi et al., Functional and molecular characterisation of mammary side population cells, Breast Cancer Res 5 (2003), R1-8.
71. R.B. Clarke et al., A putative human breast stem cell population is enriched for steroid receptor-positive cells, Dev Biol 277 (2005), 443-456. (Pubitemid 40022963)
72. R.B. Clarke, Isolation and characterization of human mammary stem cells, Cell Prolif 38 (2005), 375-386. (Pubitemid 41746370)
73. C.L. Chaffer et al., Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state, Proc Natl Acad Sci U S A 108 (2011), 7950-7955.
74. C. Brisken and S. Duss, Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective, Stem Cell Rev 3 (2007), 147-156. (Pubitemid 350129717)
75. J.E. Ferguson et al., Changes in the extracellular matrix of the normal human breast during the menstrual cycle, Cell Tissue Res 268 (1992), 167-177.
76. P.A. Joshi et al., Progesterone induces adult mammary stem cell expansion, Nature 465 (2010), 803-807.
77. M. Al-Hajj et al., Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A 100 (2003), 3983-3988. (Pubitemid 36418143)
78. L.L. Marotta and K. Polyak, Cancer stem cells: a model in the making, Curr Opin Genet Dev 19 (2009), 44-50.
79. M. Shipitsin and K. Polyak, The cancer stem cell hypothesis: in search of definitions, markers, and relevance, Lab Invest 88 (2008), 459-463. (Pubitemid 351581449)
80. N.A. Lobo et al., The biology of cancer stem cells, Annu Rev Cell Dev Biol 23 (2007), 675-699.
81. M. Shipitsin et al., Molecular definition of breast tumor heterogeneity, Cancer Cell 11 (2007), 259-273. (Pubitemid 46349843)
82. C. Hirschmann-Jax et al., A distinct "side population" of cells with high drug efflux capacity in human tumor cells, Proc Natl Acad Sci U S A 101 (2004), 14228-14233. (Pubitemid 39305058)
83. +/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis, Breast Cancer Res 8 (2006), R59.
84. T. Blick et al., Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 (hi/) CD24 (lo/-) stem cell phenotype in human breast cancer, J Mammary Gland Biol Neoplasia 15 (2010), 235-252.
85. +/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients, Med Oncol, (2010).
86. +/CD24- phenotype is enriched in basal-like breast tumors, Breast Cancer Res 10 (2008), R53.
87. S. Ricardo et al., Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype, J Clin Pathol, (2011).
88. M.J. Meyer et al., Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines, Breast Cancer Res 11 (2009), R82.
89. M.J. Meyer et al., CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer, Cancer Res 70 (2010), 4624-4633.
90. S.A.Mani et al., The epithelial-mesenchymal transition generates cells with properties of stem cells, Cell 133 (2008), 704-715.
91. G. Molyneux et al., BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells, Cell Stem Cell 7 (2010), 403-417.
92. C.L. Chaffer and R.A.Weinberg, Cancer cell of origin: spotlight on luminal progenitors, Cell Stem Cell 7 (2010), 271-272.
93. L. Melchor and J. Benitez, An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes, Carcinogenesis 29 (2008), 1475-1482.
94. N. Tung et al., Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features, Breast Cancer Res 12 (2010), R12.
95. E. Resetkova et al., Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment, Breast Cancer Res Treat 123 (2010), 97-108.
96. C. Ginestier, S. Liu and M.S. Wicha, Getting to the root of BRCA1-deficient breast cancer, Cell Stem Cell 5 (2009), 229-230.
97. A. Lapuk et al., Exon-level microarray analyses identify alternative splicing programs in breast cancer, Mol Cancer Res 8 (2010), 961-974.
98. A. Luini et al., Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature, Breast Cancer Res Treat 101 (2007), 349-353. (Pubitemid 46169889)
99. S.Y. Jung et al.,Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer, Breast Cancer Res Treat 120 (2010), 627-637.
100. B.T. Hennessy et al., Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics, Cancer Res 69 (2009), 4116-4124.
101. K. Takahashi et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell 131 (2007), 861-872. (Pubitemid 350138099)
102. S. Yamanaka and H.M. Blau, Nuclear reprogramming to a pluripotent state by three approaches, Nature 465 (2010), 704-712.
103. R.B. Clarke et al., Regulation of human breast epithelial stem cells, Cell Prolif 36(Suppl 1) (2003), 45-58. (Pubitemid 37521843)
104. Y. Dong et al., Synthetic lethality through combined Notchepidermal growth factor receptor pathway inhibition in basallike breast cancer, Cancer Res 70 (2010), 5465-5474.
105. G. Dontu et al., Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells, Breast Cancer Res 6 (2004), R605-615.
106. S.J. Zardawi et al., Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer, Histol Histopathol 24 (2009), 385-398.
107. A.I. Khramtsov et al., Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome, Am J Pathol 176 (2010), 2911-2920.
108. P. Grudzien et al., Inhibition of Notch Signaling Reduces the Stem-like Population of Breast Cancer Cells and Prevents Mammosphere Formation, Anticancer Res 30 (2010), 3853-3867.
109. K. Polyak and R.A.Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nat Rev Cancer 9 (2009), 265-273.
110. P.B. Gupta et al., Identification of selective inhibitors of cancer stem cells by high-throughput screening, Cell 138 (2009), 645-659.
111. B. Ruter, P.W.Wijermans and M. Lubbert, DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients withmyelodysplasia and acute myeloid leukemia, Int J Hematol 80 (2004), 128-135. (Pubitemid 39201565)
112. A.T. Ferguson et al., Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression, Cancer Res 55 (1995), 2279-2283.
113. X. Yang et al., Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells, Cancer Res 61 (2001), 7025-7029. (Pubitemid 32946489)
114. M. Rijnkels et al., The epigenetic landscape of mammary gland development and functional differentiation, JMammary Gland Biol Neoplasia 15 (2010), 85-100.